A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
This study examined the association between two specific polymorphisms of the gene encoding the mu-opioid receptor and treatment outcomes in alcohol-dependent patients who were prescribed naltrexone or placebo. A total of 82 patients (71 of European descent) who were randomized to naltrexone and 59 who were randomized to placebo (all of European descent) in one of three randomized, placebo-controlled clinical trials of naltrexone were genotyped at the A(+118)G (Asn40Asp) and C(+17)T (Ala6Val) SNPs in the gene encoding the mu-opioid receptor (OPRM1). The association between genotype and drinking outcomes was measured over 12 weeks of treatment. In subjects of European descent, individuals with one or two copies of the Asp40 allele treated with naltrexone had significantly lower rates of relapse (p=0.044) and a longer time to return to heavy drinking (p=0.040) than those homozygous for the Asn40 allele. There were no differences in overall abstinence rates (p=0.611), nor were there differences in relapse rates or abstinence rates between the two genotype groups among those assigned to placebo. These preliminary results are consistent with prior literature demonstrating that the opioid system is involved in the reinforcing properties of alcohol and that allelic variation at OPRM1 is associated with differential response to a mu-receptor antagonist. If replicated, these results would help to identify alcohol-dependent individuals who may be most likely to respond to treatment wit…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An initial retrospective analysis of NTX trials found that OPRM1 influenced treatment response, such that individuals with the Asp40 variant (G allele) receiving NTX had a longer time until the first heavy drinking day and were half as likely to relapse compared to those homozygous for the Asn40 variant (A allele) [92].”
From Relapse prevention for addictive behaviors (2011) · cites this paper as [92]
In the citing paper
“Interestingly, both human A118G subjects and Rhesus C77G subjects are more likely to respond positively to opioid antagonist therapy for alcoholism, which suggests that the differences in receptor properties may be a direct physiological mechanism for the increased risk for alcoholism (Oslin et al 2003).”
From The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction (2012) · cites this paper as Oslin et al 2003
Citations
Cites
(1996) · Cited by 6,884
The fifth edition of the addiction severity index
McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,222 · cited 1×
“The Addiction Severity Index (ASI) was used to measure the severity of alcoholrelated problems during the pretreatment period (McLellan et al, 1980, 1992).”
MethodSelf-citationSobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110 · cited 1×
“The Time Line Follow-Back (TLFB) method measured alcohol consumption (Sobell et al, 1988; Sobell and Sobell, 1992) during the pretreatment and treatment periods.”
MethodMcLELLAN, A. T., LUBORSKY, L., WOODY, G. E., & O??BRIEN, C. P. (1980) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198001000-00006 · Cited by 3,188
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Self-citationNew Data from the Addiction Severity Index Reliability and Validity in Three Centers
McLELLAN, A. T., LUBORSKY, L., CACCIOLA, J., GRIFFITH, J., EVANS, F., BARR, H. L., & OʼBRIEN, C. P. (1985) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198507000-00005 · Cited by 1,503 · cited 1×
“…lifetime and recent (past 30 days) severity of problems in seven areas of biopsychosocial functioning (represented by component scores): medical status, employment and self-support, alcohol use, drug use, legal status, family and social relations, and psychiatric symptoms (McLellan et al, 1985).”
BackgroundSelf-citationNaltrexone and Coping Skills Therapy for Alcohol Dependence: A Controlled Study
O'Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,487 · cited 4×
“Although this definition of heavy drinking has been used in a number of pharmacotherapy trials (O’Malley et al, 1992; Volpicelli et al, 1992; Anton, 1996; Kranzler and VanKirk, 2001), both higher and lower levels of consumption could be considered significant.”
BackgroundMethodInfluentialBond, C., LaForge, K. S., Tian, M., Melia, D., Zhang, S., Borg, L., Gong, J., Schluger, J., Strong, J. A., Leal, S. M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9608 · Cited by 1,074 · cited 3×
“…association between OPRM1 sequence variation and the presence of alcohol and/or drug dependence (Bergen et al, 1997; Berrettini et al, 1997; Bond et al, 1998; Kranzler et al, 1998; Sander et al, 1998; Gelernter et al, 1999; Town et al, 1999; Hoehe et al, 2000; Franke et al, 2001;…”
BackgroundInfluentialSOBELL, L. C., SOBELL, M. B., LEO, G. I., & CANCILLA, A. (1988) · British Journal of Addiction · doi:10.1111/j.1360-0443.1988.tb00485.x · Cited by 776 · cited 1×
“The Time Line Follow-Back (TLFB) method measured alcohol consumption (Sobell et al, 1988; Sobell and Sobell, 1992) during the pretreatment and treatment periods.”
MethodNaltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618 · cited 1×
“…advantage of naltrexone over placebo (O’Malley et al, 1992; Volpicelli et al, 1992; Oslin et al, 1997; Chick et al, 2000; Anton et al, 2001; Monti et al, 2001; Morris et al, 2001), other studies have failed to show a significant drugplacebo difference (Kranzler et al, 2000; Krystal et al, 2001).”
Background
Research works printed but not linked: 2
- Thomas C, Wallack S, Swift R, Bishop C, McCarty D, Simoni-Wastila L (2001). Adoption of naltrexone in alcoholism treatment. J Addict Dis 20: 180.
- Volpicelli JR, Pettinati HM, McLellan AT, O'Brien CP (1997). BRENDA Manual: Compliance Enhancement Techniques with Pharmacotherapy for Alcohol and Drug Dependence. Guilford press: Philadelphia.
Cited by
Items 201–300 of 572
Kranzler, H. R., Armeli, S., Covault, J., & Tennen, H. (2013) · Addiction Biology · doi:10.1111/j.1369-1600.2012.00471.x · Cited by 49
“Oslin et al. (2003) first reported a moderating effect of the polymorphism using data from three placebo-controlled trials of naltrexone.”
BackgroundMethodSelf-citationREVIEW: Non‐human primate models of inheritance vulnerability to alcohol use disorders
Barr, C. S., & Goldman, D. A. (2006) · Addiction Biology · doi:10.1111/j.1369-1600.2005.00034.x · Cited by 54
“This also parallels human findings, which indicate that the OPRM1 118G allele is associated with an increase in the number of days on which alcohol-dependent patients consume alcohol (Oslin et al. 2003).”
Result(2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.089540 · Cited by 47
An overview of the genetics of substance use disorders
Lachman, H. M. (2006) · Current Psychiatry Reports · doi:10.1007/s11920-006-0013-3 · Cited by 51
Mroziewicz, M., & Tyndale, R. F. (2010) · PubMed Central · Cited by 67
Gueorguieva, R. V., Wu, R., Pittman, B. P., Cramer, J. A., Rosenheck, R. A., O’Malley, S. S., & Krystal, J. H. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.038 · Cited by 47
“The possibility that subgroups of alcohol dependent patients might differ predictably in their response to naltrexone also has been suggested on the basis of molecular genetic data (Oslin et al 2003).”
BackgroundReward, Relief and Habit Drinking: Initial Validation of a Brief Assessment Tool
Grodin, E. N., Bujarski, S., Venegas, A., Baskerville, W., Nieto, S. J., Jentsch, D., & Ray, L. A. (2019) · Alcohol and Alcoholism · doi:10.1093/alcalc/agz075 · Cited by 50
“…responses to naltrexone are highly variable, which may be due, at least in part, to factors such as family history of alcoholism (King et al., 1997; Rubio et al., 2005; Krishnan-Sarin et al., 2007) and variation in the OPRM1 gene (Oslin et al., 2003; Ray and Hutchison, 2007; Anton et al., 2008).”
BackgroundGenetic Variability of μ-Opioid Receptor in an Obstetric Population
Landau, R., Cahana, A., Smiley, R. M., Antonarakis, S. E., & Blouin, J. (2004) · Anesthesiology · doi:10.1097/00000542-200404000-00042 · Cited by 47
Genetic influences on response to alcohol and response to pharmacotherapies for alcoholism
Enoch, M. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.11.001 · Cited by 52
“These findings are in line with another study showing that G allele carrying naltrexone-treated alcoholics had significantly lower relapse rates and took longer to return to heavy drinking thanAAhomozygotes (Oslin et al., 2003).”
ResultGarbutt, J. C., Kampov‐Polevoy, A. B., Kalka-Juhl, L. S., & Gallop, R. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.2157 · Cited by 49
The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target?
Pomrenze, M. B., Fetterly, T. L., Winder, D. G., & Messing, R. O. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13507 · Cited by 47
“…to AUD medications development, first for naltrexone response and the A118G variant in the mu opioid receptor gene OPRM1 (Anton et al., 2008; Oslin et al., 2003; Ray et al., 2012), and subsequently for ondansetron treatment and polymorphisms in the serotonin transporter gene 5-HTT (Johnson…”
COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms.
Goldman, D. A., Oroszi, G., O’Malley, S. S., & Anton, R. F. (2005) · Journal of Studies on Alcohol Supplement · doi:10.15288/jsas.2005.s15.56 · Cited by 48
The Need for Treatment Responsive Translational Biomarkers in Alcoholism Research
Heilig, M. A., Sommer, W. H., & Spanagel, R. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_5006 · Cited by 48
NIAAA: advancing alcohol research for 40 years.
Warren, K. R., & Hewitt, B. G. (2010) · PubMed Central · Cited by 48
Ayanwuyi, L. O., Carvajal, F., Lerma-Cabrera, J. M., Domi, E., Björk, K., Ubaldi, M., Heilig, M., Roberto, M., Ciccocioppo, R., & Cippitelli, A. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00023 · Cited by 44
“For example, polymorphisms in the serotonin 2A receptor gene, dopamine transporter, µ-opioid, or GABA A receptor genes have been associated with alcohol dependence (Oslin et al., 2003; Edenberg and Kranzler, 2005; Ramchandani et al., 2011; Bhaskar et al., 2012; Wrzosek et al., 2012).”
BackgroundPharmacogenetics of Drug Dependence: Role of Gene Variations in Susceptibility and Treatment
Khokhar, J. Y., Ferguson, C. S., Zhu, A. Z. X., & Tyndale, R. F. (2010) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105826 · Cited by 48
Acute Pancreatitis: Genetic Risk and Clinical Implications
Weiß, F. U., Lämmerhirt, F., & Lerch, M. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10020190 · Cited by 52
Alcohol response and consumption in adolescent rhesus macaques: life history and genetic influences
Schwandt, M. L., Lindell, S. G., Chen, S., Higley, J. D., Suomi, S. J., Heilig, M., & Barr, C. S. (2010) · Alcohol · doi:10.1016/j.alcohol.2009.09.034 · Cited by 41
“…with the observation that men generally exhibit more alcohol-induced stimulation and that alcoholdependent human subjects who are carriers of the OPRM1 A118G allele are more responsive to μ-opioid receptor blockade (Anton et al., 2008; Garbutt et al., 2005; Kim et al., 2009; Oslin et al., 2003).”
BackgroundLandau, R. (2006) · Anesthesiology · doi:10.1097/00000542-200608000-00003 · Cited by 48
The contribution of genetics to addiction therapy approaches
Edenberg, H. J., & Kranzler, H. R. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.011 · Cited by 46
Self-citationThe µ-Opioid Receptor and Treatment Response to Naltrexone
Thorsell, A. (2013) · Alcohol and Alcoholism · doi:10.1093/alcalc/agt030 · Cited by 50
“The impact of the OPRM1 A118G on treatment response to naltrexone was demonstrated by Oslin and colleagues (Oslin et al., 2003) in a meta-analysis of three previously reported clinical trials.”
MethodAdvances in Medications and Tailoring Treatment for Alcohol Use Disorder
Seneviratne, C., & Johnson, B. A. (2015) · Alcohol research · doi:10.35946/arcr.v37.1.02 · Cited by 49
Coller, J. K., Cahill, S., Edmonds, C., Farquharson, A. L., Longo, M. C., Minniti, R., Sullivan, T., Somogyi, A. A., & White, J. M. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834c5445 · Cited by 43
Nalmefene for the treatment of alcohol dependence: a current update
Soyka, M. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001284 · Cited by 47
“, 2013) and modify response to treatment with opioid antagonists such as naltrexone, although there are conflicting results (Oslin et al., 2003; McGeary et al., 2006; Gelernter et al., 2007; Anton et al., 2008, 2012; Kim et al., 2009; Koller et al., 2012; Oroszi et al., 2009; Kranzler et al., 2013).”
BackgroundResultBauer, I. E., Soares, J. C., & Nielsen, D. A. (2014) · American Journal on Addictions · doi:10.1111/ajad.12172 · Cited by 42
Emerging drugs to treat alcoholism
Soyka, M., & Rösner, S. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2010.500811 · Cited by 40
Neuropharmacology of addiction and how it informs treatment
Lingford-Hughes, A. R., Watson, B. J., Kalk, N. J., & Reid, A. G. (2010) · British Medical Bulletin · doi:10.1093/bmb/ldq032 · Cited by 43
Naltrexone long-acting formulation in the treatment of alcohol dependence.
Johnson, B. A. (2007) · PubMed Central · Cited by 42
Ripley, T. L., & Stephens, D. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01406.x · Cited by 50
“, 2005) and more effective naltrexone-mediated abstinence from alcohol (Oslin et al., 2003).”
BackgroundSher, K. J., Dick, D. M., Crabbe, J. C., Hutchison, K. E., O’Malley, S. S., & Heath, A. C. (2010) · Addiction Biology · doi:10.1111/j.1369-1600.2009.00189.x · Cited by 45
“Specifically, carriers of the OPRM1 +118G allele have been found to respond better to naltrexone therapy for alcohol dependence relative to homozygotes for the OPRM1 +118A allele (Oslin et al. 2003; Anton & Oroszi 2008), although not all studies support this finding (e.g. Gelernter et al. 2007).”
BackgroundPrecision medicine and pharmacogenetics: what does oncology have that addiction medicine does not?
Kranzler, H. R., Vickers‐Smith, R., Schnoll, R. A., Moustafa, A. F., & Akman, E. G. (2017) · Addiction · doi:10.1111/add.13818 · Cited by 42
Self-citationHartwell, E. E., Feinn, R., Morris, P. E., Gelernter, J. E., Krystal, J. H., Arias, A. J., Hoffman, M., Petrakis, I. L., Gueorguieva, R. V., Schacht, J. P., et al. (2020) · Addiction · doi:10.1111/add.14975 · Cited by 44
“Initial secondary analyses of RCTs of naltrexone for AUD showed that up to 25% of Europeans and 50% of Asians [15, 16] who were carriers of the minor Asp40 allele had better responses to naltrexone treatment than Asn40-allele homozygotes [17, 18].”
BackgroundMethodSelf-citationHenderson, A. N., & Czachowski, C. L. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3571-9 · Cited by 47
“…to the positive but not sedative effects of EtOH (Ray et al. 2013) and have a greater response to NTX treatment than those that are FH -or homozygous for the 118A allele (King et al. 1997; Oslin et al. 2003; Rubio et al. 2005; Krishnan-Sarin et al. 2007; Anton et al. 2008; Ray et al. 2012).”
Pharmacogenetics of Opiates in Clinical Practice: the Visible Tip of the Iceberg
Hajj, A., Khabbaz, L. R., Laplanche, J., & Peoc’h, K. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.13 · Cited by 41
Nylander, I., & Roman, E. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00077 · Cited by 40
“For example, several reports have shown that MOPR polymorphism affect the response to naltrexone (Oslin et al., 2003; Mague and Blendy, 2010).”
BackgroundRinker, J. A., Fulmer, D. B., Trantham-Davidson, H., Smith, M. L., Williams, R. W., Lopez, M. F., Randall, P. K., Chandler, L. J., Miles, M. F., Becker, H. C., et al. (2017) · Alcohol · doi:10.1016/j.alcohol.2016.05.007 · Cited by 40
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript Covault, et al., 2014; Oslin et al., 2003).”
BackgroundClozapine-Associated Restless Legs Syndrome
Duggal, H. S., & Mendhekar, D. N. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31802e7587 · Cited by 40
Kiefer, F., Jiménez‐Arriero, M. Á., Klein, O., Diehl, A., & Rubio, G. (2007) · Addiction Biology · doi:10.1111/j.1369-1600.2007.00073.x · Cited by 47
Alcohol–medical drug interactions
Johnson, B. A., & Seneviratne, C. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-62619-6.00031-8 · Cited by 39
Bart, G. B., LaForge, K. S., Borg, L., Lilly, C., Ho, A., & Kreek, M. J. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301128 · Cited by 38
“Whether the effectiveness of treatment agents for these disorders (such as increased treatment response to naltrexone in alcoholics with a 118G allele described by Oslin et al, 2003) may be influenced by the effects of a 118G allele on HPA axis responsiveness should also be investigated.”
BackgroundOliva, J. M., & Manzanares, J. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301237 · Cited by 43
“Bar represents 1 mm. Neuropsychopharmacology polymorphism of the m-opioid receptor gene associated with naltrexone response in alcohol-dependent patients (Oslin et al, 2003).”
BackgroundNew findings on the genetic influences on alcohol use and dependence
Higuchi, S., Matsushita, S., & Kashima, H. (2006) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000218595.54054.7a · Cited by 38
Schwandt, M. L., Lindell, S. G., Higley, J. D., Suomi, S. J., Heilig, M. A., & Barr, C. S. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.03.002 · Cited by 37
“…Oertel et al., 2006; Chou et al., 2006a,b), response to alcohol and nicotine (Ray and Hutchison, 2004; Lerman et al., 2004; Ray et al., 2006), and the therapeutic efficacy of opioid antagonists in alcohol-dependence (Oslin et al., 2003; Garbutt et al., 2005; Anton et al., 2008; Kim et al., 2009).”
Interactive Effects of OPRM1 and DAT1 Genetic Variation on Subjective Responses to Alcohol
Ray, L. A., Bujarski, S., Squeglia, L. M., Ashenhurst, J. R., & Anton, R. F. (2014) · Alcohol and Alcoholism · doi:10.1093/alcalc/agt183 · Cited by 41
“, 2010, 2011)with some clinical studies suggesting that G-allele carriers may respond better to naltrexone (Oslin et al., 2003; Anton et al., 2008), while other studies have failed to replicate”
BackgroundPharmacogenetics of alcohol use disorder treatments: an update
Hartwell, E. E., & Kranzler, H. R. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1628218 · Cited by 37
“[29](1) rs1799971 141 European Americans Alcohol dependence Asp40 carriers treated with naltrexone had a lower rate and a longer time to relapse to heavy drinking Anton et al.”
BackgroundSelf-citationPharmacotherapies and Personalized Medicine for Alcohol Use Disorder: A Review
Lohoff, F. W. (2020) · Pharmacogenomics · doi:10.2217/pgs-2020-0079 · Cited by 41
Adolescent and Young Adult Heroin Patients: Drug Use and Success in Methadone Maintenance Treatment
Kellogg, S. H., Melia, D., Khuri, E. T., Lin, A., Ho, A., & Kreek, M. J. (2006) · Journal of Addictive Diseases · doi:10.1300/j069v25n03_03 · Cited by 38
Ducat, E., Ray, B., Bart, G., Umemura, Y., Varon, J., Ho, A., & Kreek, M. J. (2013) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00313.x · Cited by 37
“…have shown that naltrexone pharmacotherapy in alcoholdependent persons is more likely to be effective in persons with the 118G variant allele (Oslin et al. 2003; Anton et al. 2008) A recent study identified an increase in the neurosteroid allopregnanolone after naltrexone administration in…”
BackgroundBujarski, S., & Ray, L. A. (2016) · Behaviour Research and Therapy · doi:10.1016/j.brat.2016.05.008 · Cited by 42
“This pharmacogenetic effect has been translated to clinical trials, however with somewhat mixed results (Anton et al., 2008; Gelernter et al., 2007; Oslin et al., 2003, 2015).”
Symbiotic relationship of pharmacogenetics and drugs of abuse
Rutter, J. L. (2006) · The AAPS Journal · doi:10.1208/aapsj080121 · Cited by 37
Effects of Alcoholism Typology on Response to Naltrexone in the COMBINE Study
Bogenschutz, M. P., Tonigan, J. S., & Pettinati, H. M. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00804.x · Cited by 41
“For example, it has been reported that patients who have the OPRM1 Asp40 allele had better treatment outcomes with naltrexone than those without it this allele (Anton et al., 2008, Oslin et al., 2003), although conflicting results were reported from the VA Alcohol Clin Exp Res.”
ResultSelf-citationCost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment
Heitjan, D. F., Asch, D. A., Ray, R., Rukstalis, M. R., Patterson, F., & Lerman, C. E. (2008) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500492 · Cited by 38
Development of medications for alcohol use disorders: recent advances and ongoing challenges
Litten, R. Z., Fertig, J. B., Mattson, M. E., & Egli, M. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.2.323 · Cited by 40
“A polymorphism in the gene that codes the μ-opioid receptor (A118G, which causes an Asn40Asp substitution in the protein) has recently been associated with the response to naltrexone in alcohol-dependent patients [51] and to a family history of alcoholism, alcohol intoxication and alcohol-induced stimulation and sedat…”
BackgroundFredriksson, I., Jayaram-Lindström, N., Wirf, M., Nylander, E., Nyström, E., Jardemark, K., & Steensland, P. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.294 · Cited by 35
“Naltrexone is mostly efficacious in AUD patients with a specific polymorphism in the m-opioid receptor gene (Oslin et al, 2003; Anton et al, 2008).”
Backgroundvan der Zwaluw, C. S., Wildenberg, E. V. D., Wiers, R. W. H. J., Franke, B., Buitelaar, J. K., Scholte, R. H. J., & Engels, R. C. M. E. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.10.1427 · Cited by 41
Neurochemical Heterogeneity of Rats Predicted by Different Measures to be High Ethanol Consumers
Barson, J. R., Fagan, S. E., Chang, G., & LEIBOWITZ, S. F. (2012) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2012.01858.x · Cited by 35
“Also, it is consistent with findings that subjects with the Asp40 allele of the mu-opioid receptor, which has greater binding affinity, are more responsive to naltrexone (Oslin et al., 2003).”
BackgroundResultRay, L. A., & Oslin, D. W. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.07.006 · Cited by 35
“All rights reserved. cipal target of naltrexone, show better treatment response to this medication, as compared to homozygotes for the major (Asn40) allele at this locus (Anton et al., 2008; Oroszi et al., 2009; Oslin et al., 2003).”
BackgroundSelf-citationProton Magnetic Resonance Spectroscopy in Alcohol Use Disorders: A Potential New Endophenotype?
Meyerhoff, D. J., & Durazzo, T. C. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00695.x · Cited by 37
“…have a significant impact on cueinduced craving for alcohol in heavy drinkers (van den Wildenberg et al., 2007), response to naltrexone treatment in alcohol dependent patients (McGeary et al., 2006; Oslin et al., 2003), as well as responses to alcohol (Barr et al., 2007; Ray and Hutchison, 2004).”
BackgroundMetabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects
Hinton, D. J., Vázquez, M. S., Geske, J. R., Hitschfeld, M. J., Ho, A. M., Karpyak, V. M., Biernacka, J. M., & Choi, D. (2017) · Scientific Reports · doi:10.1038/s41598-017-02442-4 · Cited by 38
Kreek, M. J., Schlussman, S. D., Bart, G. B., LaForge, K. S., & Butelman, E. R. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.024 · Cited by 36
Pharmacological management of alcohol dependence: From mono-therapy to pharmacogenetics and beyond
Caputo, F., Vignoli, T., Grignaschi, A., Cibin, M., Addolorato, G., & Bernardi, M. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.10.004 · Cited by 36
“, 1997) and the presence of a specific polymorphism (Asn40Asp) in the m-opioid receptor gene (Oslin et al., 2003; Anton et al., 2008) appear to predict a positive response to NTX.”
BackgroundSchick, M. R., Spillane, N. S., & Hostetler, K. L. (2020) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14440 · Cited by 35
Pharmacogenetics of Addiction Therapy
Nielsen, D. A., Nielsen, E. M., Dasari, T., & Spellicy, C. J. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0956-8_15 · Cited by 33
Recent advances in the pharmacotherapy of alcoholism
Myrick, H., & Anton, R. F. (2004) · Current Psychiatry Reports · doi:10.1007/s11920-004-0019-7 · Cited by 35
Predicting cocaine group treatment outcome in cocaine-abusing methadone patients.
Tzilos, G. K., Rhodes, G. L., Ledgerwood, D. M., & Greenwald, M. K. (2009) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0016835 · Cited by 35
“Pharmacogenetic studies are exploring the relationship of individual genetic differences to medication outcomes (e.g., Lerman et al., 2006; Oslin et al., 2003).”
BackgroundGfi-1 takes center stage in hematopoietic stem cells
Duan, Z., & Horwitz, M. S. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.12.003 · Cited by 40
Codeine and Tramadol Use in Athletes: A Potential for Abuse
Zandonai, T., Escorial, M., & Peiró, A. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.661781 · Cited by 33
“It has been observed that the presence of heterozygotes (A/G) affects its affinity for beta-endorphin, increasing it (Oslin et al., 2003) and, thus creating need for modified dosage of opioids.”
BackgroundThe Pharmacotherapy of Alcohol Dependence: A State of the Art Review
Sousa, A. D. (2010) · Mens Sana monographs · doi:10.4103/0973-1229.58820 · Cited by 32
Crist, R. C., Doyle, G. A. R., Nelson, E. C., Degenhardt, L. J., Martin, N. G., Montgomery, G. W., Saxon, A. J., Ling, W. W., & Berrettini, W. H. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.89 · Cited by 31
Self-citationLitten, R. Z., Falk, D. E., Ryan, M. L., Fertig, J. B., & Leggio, L. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14233 · Cited by 31
Medications for unhealthy alcohol use: across the spectrum.
O’Malley, S. S., & O’Connor, P. G. (2011) · PubMed Central · Cited by 38
The opioid receptors as targets for drug abuse medication
Noble, F., Lenoir, M., & Marie, N. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13190 · Cited by 36
“Interestingly, some factors that contribute to a naltrexone-positive response have been identified, such as the MOP receptor single-nucleotide polymorphism A118G (Oslin et al., 2003; Anton et al., 2008) and adherence to treatment (Chick et al., 2000; Krystal et al, 2001).”
BackgroundChoosing the right medication for the treatment of alcoholism
Pettinati, H. M., & Rabinowitz, A. R. (2006) · Current Psychiatry Reports · doi:10.1007/s11920-006-0040-0 · Cited by 33
Self-citationReview: Pharmacogenetics of alcoholism treatment: Implications of ethnic diversity
Cservenka, A., Yardley, M. M., & Ray, L. A. (2016) · American Journal on Addictions · doi:10.1111/ajad.12463 · Cited by 30
Naltrexone in the Treatment of Alcohol Dependence
Unterwald, E. M. (2008) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e318182b20f · Cited by 32
Suh, J. J., Pettinati, H. M., Kampman, K. M., & O’Brien, C. P. (2008) · American Journal on Addictions · doi:10.1080/10550490802409074 · Cited by 30
Self-citationAlteraciones neurobiológicas en el alcoholismo: revisión
Erdozain, A. M., & Callado, L. F. (2014) · Adicciones · doi:10.20882/adicciones.40 · Cited by 29
Anton, R. F., Latham, P. K., Voronin, K. E., Randall, P. K., Book, S. W., Hoffman, M., & Schacht, J. P. (2018) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13601 · Cited by 30
“…OPRM1 A118G, which codes for an aspartate substitution for asparagine (Asp40Asn) in the coding region of the gene, might predict naltrexone response (Anton et al., 2008; Oslin et al., 2003; Ray et al., 2012) in AUD, recent studies have been inconsistent (Oslin et al., 2015; Setiawan et al., 2012).”
Sloan, M. E., Klepp, T., Gowin, J. L., Swan, J. E., Sun, H., Stangl, B. L., & Ramchandani, V. A. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-017-0002-8 · Cited by 34
A Rational Approach to the Pharmacotherapy of Alcohol Dependence
Petrakis, I. L. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000248602.68607.81 · Cited by 32
Barr, C. S. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_142 · Cited by 28
Bidirectional translational research: Progress in understanding addictive diseases
Kreek, M. J., Schlussman, S. D., Reed, B., Zhang, Y., Nielsen, D. A., Levran, O., Zhou, Y., & Butelman, E. R. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.042 · Cited by 28
“This prediction has been borne out in two studies, a non-prospective study (Oslin et al., 2003) and a large prospective study (Anton et al., 2008), which have shown that alcohol-dependent subjects with one or two copies of the 118G allele were more responsive to naltrexone pharmacotherapy.”
ResultMcGeary, J. E., Esposito-Smythers, C. L., Spirito, A., & Monti, P. M. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.11.001 · Cited by 28
“Moreover, positive results might suggest the possibility of matching pharmacological treatments to genetic background as has been suggested in the adult literature (Oslin et al., 2003).”
BackgroundMolecular Genetics and New Medication Strategies for Opioid Addiction
Hurd, Y. L., & O’Brien, C. P. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18030352 · Cited by 28
Self-citationFMRI-based prediction of naltrexone response in alcohol use disorder: a replication study
Bach, P., Weil, G., Pompili, E., Hoffmann, S., Hermann, D., Vollstädt‐Klein, S., Kiefer, F., Mann, K. F., & Sommer, W. H. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01259-7 · Cited by 29
Opioid Receptor Polymorphism A118G Associated with Clinical Severity in a Drug Overdose Population
Manini, A. F., Jacobs, M. M., Vlahov, D., & Hurd, Y. L. (2013) · Journal of Medical Toxicology · doi:10.1007/s13181-012-0286-3 · Cited by 31
“For example, the opioid system is a convergent neuronal pathway for most drugs of abuse thus even opioid antagonist medications such as naltrexone are useful for treating alcoholics based on their OPRM1 genotype [23, 26].”
BackgroundMethodAL-Eitan, L. N., Jaradat, S. A., Su, S., Tay, G. K., & Hulse (2012) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s33351 · Cited by 31
Preuss, U. W., Wurst, F., Ridinger, M., Rujescu, D., Fehr, C., Koller, G., Bondy, B., Wodarz, N., Soyka, M., & Zill, P. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.07.002 · Cited by 29
Koller, G., Zill, P., Rujescu, D., Ridinger, M., Pogarell, O. M., Fehr, C., Wodarz, N., Bondy, B., Soyka, M., & Preuss, U. W. (2012) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2011.01714.x · Cited by 27
Human pharmacology for addiction medicine
Quednow, B. B., & Herdener, M. (2015) · Progress in brain research · doi:10.1016/bs.pbr.2015.07.017 · Cited by 28
“…clinical trial data pointed to a modulation of relapse rates in naltrexone-treated patients by a functional polymorphism of the mu-opioid receptor (Oslin et al., 2003), more recent prospective investigations could not confirm that this polymorphism can predict treatment response to naltrexone…”
ResultZalewska-Kaszubska, J., Górska, D., Dyr, W., & Czarnecka, E. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.07.028 · Cited by 27
Alcohol Use and Anxiety: Diagnostic and Management Issues
Brady, K. T., Tolliver, B. K., & Verduin, M. L. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.2.217 · Cited by 32
Chapter 2. Genetics and Epigenetics of Addiction
Gelernter, J. E., & Polimanti, R. A. (2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615373970.kb02 · Cited by 27
Self-citationWang, Y., Huang, P., Blendy, J. A., & Liu‐Chen, L. (2012) · Addiction Biology · doi:10.1111/j.1369-1600.2012.00484.x · Cited by 26
“Clinical studies revealed that among alcohol-dependent patients treated with naltrexone, those with one or two copies of the G118 allele had better outcome (Oslin et al. 2003; Kim et al. 2009).”
BackgroundNalmefene for treatment of alcohol dependence
Soyka, M., & Rösner, S. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.522990 · Cited by 29
“More of clinical relevance, the polymorphisms of the OPRM1 gene may also moderate the effects of opioid antagonists on alcohol cue reactivity and response to treatment with opioid antagonists such as naltrexone [24,29-33].”
BackgroundResultAssociation of VMAT2 gene polymorphisms with alcohol dependence
Fehr, C., Sommerlad, D., Sander, T., Anghelescu, I. G., Dahmen, N., Szegedi, A., Mueller, C., Zill, P., Soyka, M., & Preuss, U. W. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-0996-y · Cited by 27
Jonas, D. E., Amick, H. R., Feltner, C., Wines, R., Shanahan, E., Rowe, C. J., & Garbutt, J. C. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.121 · Cited by 28
“One additional study (Oslin et al., 2003) was identified that did not meet our inclusion criteria because of the study design [27].”
BackgroundPharmacotherapy of Alcohol Use Disorders and Concurrent Psychiatric Disorders: A Review
Lev-Ran, S., Balchand, K., Lefebvre, L., Araki, K. F., & Le Foll, B. (2012) · The Canadian Journal of Psychiatry · doi:10.1177/070674371205700603 · Cited by 26
Predictors for the Efficacy of Naltrexone Treatment in Alcohol Dependence: Sweet Preference
Лааксонен, Э., Lahti, J. M. T., Sinclair, J. D., Heinälä, P., & Alho, H. (2011) · Alcohol and Alcoholism · doi:10.1093/alcalc/agq101 · Cited by 26
“, 2005) and the 118G allele for the opiate μ receptor (Oslin et al., 2003), which has a greater affinity for endorphins (Bond et al.”
BackgroundWhat the alcohol doctor ordered from the neuroscientist
Heilig, M., & Leggio, L. (2016) · Progress in Brain Research · doi:10.1016/bs.pbr.2015.07.023 · Cited by 25
Metadata
- Authors
- Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P.
- Affiliations
- University of Pennsylvania (US)
- University of Connecticut (US)
- Yale University (US)
- Corresponding author
- Oslin, David W
- Venue
- Neuropsychopharmacology
- Published
- 2003-04-23
- Volume
- 28
- Issue
- 8
- Pages
- 1546-1552
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2074406420
- Cited by
- 571
- References
- 50
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 4 · 2023: 3 · 2022: 7 · 2021: 9 · 2020: 13 · 2019: 18 · 2018: 13 · 2017: 13 · 2016: 20 · 2015: 31 · 2014: 36 · 2013: 34 · 2012: 58
- FWCI
- 10.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- University of Pennsylvania
- National Alliance for Research on Schizophrenia and Depression
- National Institutes of Health (5r01aa011062-05, AA03510)
- U.S. Public Health Service
- National Institute on Alcohol Abuse and Alcoholism (AA11330, AA-07517, R01AA011330, AA 13736, AA-03510, K24AA013736, AA 11062)
- National Institute of Mental Health (K08MH001599, MH 01599)
- National Institute on Drug Abuse (R01DA014008, DA 11385, DA 14008, DA001586)
- National Center for Research Resources (RR-06192, M01RR006192)
- NIH Clinical Center
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- mu-opioid receptor, OPRM1, naltrexone, alcoholism, genetic polymorphism, treatment response, relapse, abstinence, opioid system, pharmacogenetics
- MeSH terms
- Adult, Alcoholism, Female, Gene Frequency, Humans, Male, Middle Aged, Naltrexone, Polymorphism, Genetic, Confidence Intervals, Logistic Models, Odds Ratio, Survival Analysis, Receptors, Opioid, mu
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.